Recurrent Head News Today

NT219 recommended dose established, anti-tumor activity demonstrated REHOVOT, Israel, Feb. 13, 2024 --  Purple Biotech Ltd. , a clinical-stage company developing first-in-class therapies...

/PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to...

Data reported at the 2022 Annual Meeting of the American Society for Clinical OncologyNBTXR3 is being developed as a product candidate with potential to integrate across the standards of care in oncology, and these data from collaborator-sponsored phase 1b/2 studies add support for the radioenhancer in combination w...

Data reported at the 2022 Annual Meeting of the American Society for Clinical Oncology NBTXR3 is being developed as a product candidate with potential to integrate across the standards of care

Regulatory News: NANOBIOTIX (Euronext: NANO NASDAQ: NBTX the "Company"), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the presentation of three abstracts featur...

The Royal Marsden NHS Foundation Trust has brought together world-class clinicians to advance research into the disease. Head and neck cancer is an umbrella term for cancers of the nose, mouth, throat, voice box, thyroid and salivary glands. It is the eighth most common form of cancer in the UK with over 12,000 cases diagnosed each year. It is currently estimated that between 20 and 40 per cent of head and neck cancers will return after treatment. The International Centre for Recurrent Head and...